Bellerophon Therapeutics we are a clinical-stage biotherapeutics company focused on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. We are currently developing three product candidates under our INOpulse platform, a proprietary pulsatile nitric oxide device system. The first is for the treatment of pulmonary arterial hypertension (PAH) , which is currently in Phase 3 clinical testing. The other two product candidates are for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) which are both in Phase 2 development.
|Bank Name||Bellerophon Therapeutics, Inc.|
|CEO||Mr. Fabian Tenenbaum|